D-iva
Phase 1
Vertex PharmaceuticalsD-iva is one of 43 therapeutic programs targeting Cystic Fibrosis. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
42
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
107 competitors in Cystic Fibrosis
#DrugCompanyPhaseTrials
1Ibsrela
AArdelyx
Phase 3
Zyvox
PfizerPhase 2
HSK31858
Haisco Pharmaceutical Group Co., Ltd.Phase 3
Sirturo
WWim Janssens
Phase 2
ELX/TEZ/IVA
Vertex PharmaceuticalsPhase 3
Trikafta
NNottingham University Hospitals NHS Trust
Phase 3
VNZ/TEZ/D-IVA
Vertex PharmaceuticalsPhase 3
VX-121/TEZ/D-IVA
Vertex PharmaceuticalsPhase 3
Hyperpolarized Xenon-129
TThunder Bay Regional Health Research Institute
Phase 3
Verapamil Hydrochloride
Mylan Pharmaceuticals IncPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for D-iva. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1[1]
- Company